JSPR Stock Summary and Trading Ideas (Jasper Therapeutics - Class A | NASDAQ:JSPR)

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Jasper Therapeutics - Class A trades on the NASDAQ stock market under the symbol JSPR.

As of September 17, 2026, JSPR stock price climbed to $0.64 with 151,914 million shares trading.

JSPR has a beta of 2.96, meaning it tends to be more sensitive to market movements. JSPR has a correlation of 0.10 to the broad based SPY ETF.

JSPR has a market cap of $21.30 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, JSPR traded as high as $31.01 and as low as $.32.

The top ETF exchange traded funds that JSPR belongs to (by Net Assets): VTI, VXF.

JSPR has underperformed the market in the last year with a price return of -73.7% while the SPY ETF gained +16.4%. However, in the short term, JSPR had mixed performance relative to the market. It has outperformed in the last 3 months, returning +41.5% vs +1.6% return in SPY. But in the last 2 weeks, JSPR shares have been beat by the market, returning -9.2% compared to an SPY return of -0.6%.

JSPR support price is $.54 and resistance is $.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JSPR shares will trade within this expected range on the day.